Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy

BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapy has been used to treat pediatric refractory or relapsed mature B-cell non-Hodgkin lymphoma (r/r MB-NHL) with significantly improved outcomes, but a proportion of patients display no response or experience relapse after treatment. To investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yang, Liu, Yang, Yang, Keyan, Jin, Ling, Yang, Jing, Huang, Shuang, Liu, Ying, Hu, Bo, Liu, Rong, Liu, Wei, Liu, Ansheng, Zheng, Qinlong, Zhang, Yonghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657579/
https://www.ncbi.nlm.nih.gov/pubmed/37981695
http://dx.doi.org/10.1186/s12935-023-03122-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657579/
https://www.ncbi.nlm.nih.gov/pubmed/37981695
http://dx.doi.org/10.1186/s12935-023-03122-2

Ejemplares similares